An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease Clinical Trial

Official title:
An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

Status Completed

Clinical Trial Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease

Clinical Trial Description

This is the open-label extension to the randomized, double-blind, placebo- and ropinirole-controlled SP513 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00599196
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 3
Start date	August 2002
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00269516` - SLV308 for Treatment of Patients With Early Parkinson's Disease	Phase 3
Completed	`NCT00623324` - The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease	Phase 2
Completed	`NCT00332917` - An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients	Phase 3
Completed	`NCT00335374` - An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients	Phase 3